Lexicon Pharmaceuticals Q2 2024 GAAP EPS $(0.17) Beats $(0.19) Estimate, Sales $1.647M Miss $2.831M Estimate
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported Q2 2024 GAAP EPS of $(0.17), beating the $(0.19) estimate, but sales of $1.647M missed the $2.831M estimate. EPS improved by 22.73% YoY, while sales increased by 419.56% YoY.
August 01, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Lexicon Pharmaceuticals reported Q2 2024 GAAP EPS of $(0.17), beating the $(0.19) estimate, but sales of $1.647M missed the $2.831M estimate. EPS improved by 22.73% YoY, while sales increased by 419.56% YoY.
While Lexicon Pharmaceuticals beat EPS estimates and showed significant YoY improvement in both EPS and sales, the substantial miss on sales estimates could neutralize the positive EPS news. This mixed result is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100